Buy Perjeta (Pertuzumab)

What is Perjeta (pertuzumab) for?

Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer^[1,2,3].

How does Perjeta (pertuzumab) work?

Perjeta (pertuzumab) is used in combination with trastuzumab and docetaxel (other cancer medicines) for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease^[1,2,3].

It is also used in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer^[1,2,3].

Is Perjeta (pertuzumab) approved?

Perjeta (pertuzumab) was approved for HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy by:

• FDA (USA) on June 12, 2012^[5]
• EMA (EU) on March 4, 2013^[2]
• TGA (AUS) on May 6, 2013^[3]
• Health Canada on May 8, 2013^[7]
• Medsafe (New Zealand) on July 18, 2013^[8]

How do I take Perjeta (pertuzumab)?

The standard dosage is:

• Initial dose: 840 mg administered as a 60-minute intravenous infusion
• Following infusions: 420 mg administered as a 30 to 60-minute intravenous infusion every 3 weeks.

Patients with metastatic breast cancer should be treated with pertuzumab and trastuzumab until disease progression or unmanageable toxicity.

Patients in neoadjuvant treatment of breast cancer should be administered pertuzumab every 3 weeks for 3 to 6 cycles before surgery.

Complete information about Perjeta (pertuzumab) dosage and administration can be found in the references section^[2,3,5].

Note: Consult your treating doctor for personalised dosing.

Common side effects of Perjeta (pertuzumab)

The most common side effects with Perjeta given with trastuzumab and chemotherapy are^[4]:

• diarrhoea
• alopecia (hair loss)
• nausea
• neutropenia (low levels of neutrophils, a type of white blood cell important for fighting infections).

Serious side effects of Perjeta (pertuzumab)

The most common serious side effects include^[4]:

• febrile neutropenia (low levels of neutrophils with fever)
• serious diarrhoea
• leucopenia (low white blood cell counts)
• neutropenia.

References

1. Summary of Product Characteristics [FDA]: Perjeta (pertuzumab) [PDF[
Genentech, Dec. 2017

2. Summary of Product Characteristics [EMA]: Perjeta (pertuzumab) [PDF] Roche, Jan. 2018

3. Summary of Product Characteristics [TGA]: Perjeta (pertuzumab) [PDF] Roche, Aug. 2016

4. Human Medicines: Perjeta (pertuzumab)
EMA, cited June 2017

5. FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
Roche Media Release, June 2012

6. Relevance of pCR in Breast Cancer Trials
Sikov W.M.  Sept 2014

7. Product monograph [Health Canada]: Perjeta (pertuzumab) [PDF] Hoffmann-La Roche, May 2013

8. Product detail [Medsafe]: Perjeta (pertuzumab)
Roche, July 2013